Parents sue for daughter to use medical marijuana

An 11-year-old girl with leukemia suffers seizures due to years of chemotherapy. Her parents are suing the Chicago school district for banning her use of medical marijuana.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news

Related Links:

Conclusion: Nasogastric tube syndrome is a potentially life-threatening condition and has to be considered as a possibility in immune-compromised patients who present with voice change and stridor after nasogastric tube insertion.
Source: Journal of Bronchology and Interventional Pulmonology - Category: Respiratory Medicine Tags: Case Reports Source Type: research
Publication date: Available online 20 September 2018Source: Best Practice &Research Clinical HaematologyAuthor(s): Kathryn G. RobertsAbstractPhiladelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL), or BCR-ABL1-like ALL, is a high-risk subtype of B-cell precursor ALL characterized by a gene expression profile similar to Ph-positive ALL, a high frequency of IKZF1 alterations, and poor outcome. The prevalence of Ph-like ALL is common among all ages, ranging from 10%-15% in children to over 25% in young adults. Patients with Ph-like ALL harbor a diverse range of genetic alterations that activate cytokine re...
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research
Publication date: Available online 20 September 2018Source: Best Practice &Research Clinical HaematologyAuthor(s): Mark R. LitzowAbstractBefore the advent of tyrosine kinase inhibitors (TKIs), Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL) was associated with dismal survival without allogeneic hematopoietic stem cell transplantation (allo-HSCT). Recent evidence has demonstrated that the combination of TKI and chemotherapy can result in a high rate of complete remission, thereby enabling more patients to proceed to allo-HSCT. However, with more studies reporting non-inferior outcomes with TKI and chemother...
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research
Publication date: Available online 20 September 2018Source: Best Practice &Research Clinical HaematologyAuthor(s): Frederick R. AppelbaumThe persistence of measurable residual disease (MRD) following induction chemotherapy is the single most powerful prognostic factor available to clinicians treating patients with acute myeloid leukemia (AML). How to use this information to guide subsequent therapy is complex, and influenced by the category of AML being treated, the assays used to measure MRD, MRD levels and kinetics, and the spectrum of therapies available to the patient. In this literature-based review, each of these...
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research
Publication date: Available online 20 September 2018Source: Best Practice &Research Clinical HaematologyAuthor(s): John S. WelchTP53 mutated acute myeloid leukemia (AML) responds poorly to chemotherapy and has a short overall survival rate with a median of 5-9 months. Poor outcomes in TP53 mutated AML following chemotherapy have been observed and treatment options remain limited, although the presence of TP53 mutations alone should not be a barrier to therapy. Decitabine is emerging as an alternative treatment option for patients with TP53 mutated AML, although the agent has not been associated with deep molecular remi...
Source: Best Practice and Research Clinical Haematology - Category: Hematology Source Type: research
Publication date: Available online 19 September 2018Source: Advances in Biological RegulationAuthor(s): Mariana L. Oliveira, Padma Akkapeddi, Daniel Ribeiro, Alice Melão, João T. BarataAbstractInterleukin 7 (IL-7) and its receptor (IL-7R, a heterodimer of IL-7Rα and γc) are essential for normal lymphoid development. In their absence, severe combined immunodeficiency occurs. By contrast, excessive IL-7/IL-7R-mediated signaling can drive lymphoid leukemia development, disease acceleration and resistance to chemotherapy. IL-7 and IL-7R activate three main pathways: STAT5, PI3K/Akt/mTOR and MEK/Erk, u...
Source: Advances in Biological Regulation - Category: Biology Source Type: research
Authors: Laflamme N, Préfontaine P, Lampron A, Rivest S Abstract Bone marrow transplantation is the standard of care for a host of diseases such as leukemia and multiple myeloma, as well as genetically inherited metabolic diseases affecting the central nervous system. In mouse models, bone marrow transplantation has proven a valuable tool for understanding the hematopoietic system and the homing of hematopoietic cells to their target organs. Many techniques have been developed to create chimeric mice, animals with a hematopoietic system derived from a genetic background that differs from the rest of the body...
Source: Current Protocols in Immunology - Category: Allergy & Immunology Tags: Curr Protoc Immunol Source Type: research
s Pabst While the majority of patients with acute myeloid leukemia (AML) are above the age of 65 years at diagnosis, the outcome of older AML patients remains disappointing. Even if standard intensive chemotherapy induces morphologic complete remission (CR1), relapses in older AML patients are common leading to poor long-term survival outcomes. Since autologous hematopoietic stem cell transplantation (HCT) offers distinct anti-leukemic effectiveness while avoiding graft-versus-host disease associated with allogeneic transplantation, it represents an option for consolidation treatment in selected older AML patients. How...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
High-dose chemotherapy (HD-CHT) followed by autologous blood stem cell transplantation (ABSCT) represents a standard therapy for a variety of malignant and non-malignant diseases, including leukemia, lymphoid malignancies, multiple myeloma (MM), solid tumors (e.g., germ cell tumors, sarcoma), amyloid light chain (AL) amyloidosis and autoimmune disorders.1-5 Peripheral blood stem cells (PBSCs) have become the most widely used source for hematopoietic stem cells in this setting.6,7 Considering the difficulties of collecting an additional PBSC graft after the initial myeloablative HD-CHT and ABSCT, many centers routinely coll...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Myeloid malignancies such as acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS), are potentially life-threatening diseases of the elderly, occurring mostly in the seventh to eighth decades of life 1,2. The general approach to treatment is a form of induction chemotherapy followed by consideration of allogeneic hematopoietic cell transplant (allo-HCT) as consolidation therapy in select patients felt to have high-risk disease and be fit for transplantation. Historically, allo-HCT was reserved for young patients with an acceptable performance status but with the adaptation of reduced intensity and non-myeloab...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
More News: Chemotherapy | Girls | Health | Leukemia